Cooper Companies (NASDAQ:COO) Stock Price Expected to Rise, Needham & Company LLC Analyst Says

Cooper Companies (NASDAQ:COO) had its target price hoisted by investment analysts at Needham & Company LLC from $99.00 to $101.00 in a research report issued on Friday,Benzinga reports. The brokerage presently has a “buy” rating on the medical device company’s stock. Needham & Company LLC’s target price indicates a potential upside of 31.94% from the company’s current price.

A number of other research analysts also recently commented on COO. Mizuho set a $100.00 target price on Cooper Companies and gave the company an “outperform” rating in a research note on Friday, December 5th. Morgan Stanley lifted their price target on Cooper Companies from $76.00 to $83.00 and gave the company an “equal weight” rating in a report on Monday, December 8th. Rothschild & Co Redburn cut Cooper Companies from a “buy” rating to a “neutral” rating and set a $85.00 price target for the company. in a research note on Wednesday. Piper Sandler restated an “overweight” rating and issued a $94.00 price objective (up from $83.00) on shares of Cooper Companies in a report on Friday, December 5th. Finally, The Goldman Sachs Group reaffirmed a “sell” rating and set a $73.00 price objective on shares of Cooper Companies in a research report on Friday, January 9th. One equities research analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating, seven have issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat, Cooper Companies has a consensus rating of “Moderate Buy” and an average target price of $90.79.

Cooper Companies Price Performance

Shares of COO opened at $76.55 on Friday. The business’s 50-day moving average is $82.11 and its 200-day moving average is $75.98. The company has a debt-to-equity ratio of 0.30, a current ratio of 1.89 and a quick ratio of 1.13. The company has a market capitalization of $14.94 billion, a price-to-earnings ratio of 37.90, a P/E/G ratio of 2.19 and a beta of 1.02. Cooper Companies has a fifty-two week low of $61.78 and a fifty-two week high of $89.83.

Cooper Companies (NASDAQ:COO) last posted its quarterly earnings results on Thursday, March 5th. The medical device company reported $1.10 EPS for the quarter, topping the consensus estimate of $1.03 by $0.07. The business had revenue of $1.02 billion during the quarter, compared to analysts’ expectations of $1.02 billion. Cooper Companies had a net margin of 9.67% and a return on equity of 10.36%. The firm’s quarterly revenue was up 6.2% compared to the same quarter last year. During the same period last year, the company posted $0.92 earnings per share. Cooper Companies has set its Q2 2026 guidance at 4.580-4.660 EPS. Equities research analysts expect that Cooper Companies will post 3.98 EPS for the current fiscal year.

Insider Activity

In other news, CEO Albert G. White III acquired 10,000 shares of Cooper Companies stock in a transaction dated Tuesday, December 16th. The stock was acquired at an average cost of $80.80 per share, for a total transaction of $808,000.00. Following the completion of the purchase, the chief executive officer owned 236,151 shares of the company’s stock, valued at $19,081,000.80. This represents a 4.42% increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which is accessible through this link. Also, insider Holly R. Sheffield bought 1,230 shares of the stock in a transaction that occurred on Tuesday, December 16th. The stock was purchased at an average price of $80.75 per share, for a total transaction of $99,322.50. Following the completion of the purchase, the insider directly owned 39,052 shares in the company, valued at $3,153,449. The trade was a 3.25% increase in their position. The disclosure for this purchase is available in the SEC filing. Over the last ninety days, insiders have purchased 16,014 shares of company stock valued at $1,304,416. Insiders own 2.08% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the company. Root Financial Partners LLC lifted its holdings in shares of Cooper Companies by 104.5% during the fourth quarter. Root Financial Partners LLC now owns 317 shares of the medical device company’s stock worth $26,000 after buying an additional 162 shares during the last quarter. Bell Investment Advisors Inc grew its position in Cooper Companies by 106.3% in the 3rd quarter. Bell Investment Advisors Inc now owns 425 shares of the medical device company’s stock worth $29,000 after purchasing an additional 219 shares during the last quarter. CYBER HORNET ETFs LLC bought a new position in shares of Cooper Companies during the 2nd quarter worth about $36,000. True Wealth Design LLC raised its position in shares of Cooper Companies by 484.8% during the fourth quarter. True Wealth Design LLC now owns 462 shares of the medical device company’s stock valued at $38,000 after buying an additional 383 shares during the last quarter. Finally, Cromwell Holdings LLC lifted its stake in shares of Cooper Companies by 128.8% in the fourth quarter. Cromwell Holdings LLC now owns 485 shares of the medical device company’s stock valued at $40,000 after buying an additional 273 shares during the period. Institutional investors and hedge funds own 24.39% of the company’s stock.

Key Cooper Companies News

Here are the key news stories impacting Cooper Companies this week:

• Positive Sentiment: Q1 beat and guidance lift — COO reported a Q1 EPS beat and management raised FY26 EPS and free‑cash‑flow guidance, citing robust momentum in MyDay and MiSight and margin expansion. This is the main fundamental positive supporting longer‑term upside. Read More.
• Positive Sentiment: Bullish analyst activity — Multiple firms increased targets/ratings today (Barclays raised its target to $103 and Needham to $101; William Blair maintained a Buy), signaling continued conviction from several sell‑side analysts. This creates potential catalyst if buyers follow through. Read More.
• Neutral Sentiment: Favorable growth profile highlighted by screens — Recent writeups (Zacks, other screens) point to above‑average financial growth and attractive style scores, which may keep the stock on growth‑oriented portfolios but don’t guarantee near‑term momentum. Read More.
• Neutral Sentiment: Product/clinical news supports long run thesis — CooperVision research and product initiatives were highlighted at NCC 2026, reinforcing the durability of the contact‑lens franchise. That’s positive strategically but not an immediate catalyst. Read More.
• Negative Sentiment: Market punished the stock despite the beat — Several outlets noted shares fell after the report because revenue was roughly in‑line or slightly short of some street models and investors flagged regional headwinds and sluggish core vision trends. That helped drive the intraday selloff. Read More.
• Negative Sentiment: Mixed analyst/street positioning — Citigroup trimmed its target to $87 and issued Neutral, and Morgan Stanley stayed on Hold, reflecting differing views on near‑term recovery in core vision that can limit upside until clearer top‑line improvement is visible. Read More.

About Cooper Companies

Cooper Companies, Inc (NASDAQ: COO) is a global medical device company headquartered in San Ramon, California. Founded in 1958, the company has grown through strategic acquisitions and organic development to become a major provider of vision care and women’s health products. Cooper Companies operates through two primary business segments—CooperVision and CooperSurgical—each serving specialized markets within the healthcare industry.

The CooperVision segment develops, manufactures and markets a broad range of soft contact lenses, as well as related accessories.